Progress of bispecific antibodies in treatment of multiple myeloma / 白血病·淋巴瘤

ABSTRACT

Multiple myeloma is a malignant disorder of plasma cells. Although the prognosis of MM patients has improved significantly with the widespread use of new targeted drugs such as immunomodulators, proteasome inhibitors and autologous hematopoietic stem cell transplantation, the disease will eventually recur and progress. In recent years, immunotherapy has made breakthroughs in the treatment of MM, chimeric antigen receptor T-cell therapy, antibody conjugate drugs and bispecific antibodies have shown significant effectiveness and good safety at different stages of the disease. Bispecific antibodies, which bind both CD3 on T cells and target molecules on the surface of malignant plasma cells, are effective immunotherapeutic agents for patients with relapsed/refractory MM. This article reviews the research progress of bispecific antibodies in the treatment of MM in conjunction with the reports at the 64th American Society of Hematology Annual Meeting.